Fulcrum Therapeutics, Inc. (NASDAQ: FULC) is a Healthcare company (Biotechnology) with a market capitalization of $286M. The Maz Rating grades it against the other companies in its sector.
Fulcrum Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.75, Fulcrum Therapeutics, Inc. trades at 0.9x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -23.6%, return on invested capital of -24.7% and a free cash flow yield of -22.9%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 36.19. Over the past 52 weeks the share price ranged from $2.83 to $15.74, with a beta of 2.77.
Fulcrum Therapeutics, Inc. does not currently pay a dividend.
17 Wall Street analyst ratings cover the stock: 7 Buy, 7 Hold and 3 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Fulcrum Therapeutics, Inc. (FULC) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 106.9% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 106.9% / 33% · Receivables / Mkt Cap (36m) 0.46% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 106.9% / 33.33% · Receivables / Mkt Cap (24m) 0.46% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.55% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 97.3% / 33.33% · Receivables / Avg Assets (4Q) 0.46% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 98.6% / 33.33% · (Cash+Recv) / Total Assets 99.1% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, Fulcrum Therapeutics, Inc. (FULC) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Fulcrum Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
Fulcrum Therapeutics, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.